Crucell has nailed a $70 million contract from the National Institutes of Allergy and Infectious Diseases to develop new vaccines to combat the Ebola and Marburg viruses. That contract will be worth
A joint venture between Crucell and DSM Biologics- Percivia-- has produced a new, more efficient approach to manufacturing monoclonal antibodies and proteins. By relying on human cell lines rather
Shares of Crucell jumped after the developer announced that an early-stage trial of an experimental tuberculosis vaccine demonstrated a promising immune response in volunteers. The Dutch biotech is
The Dutch developer Crucell has opted to shelve its development program for a West Nile vaccine after seeing a drop in the number of people infected by the virus in the U.S. That was a surprise move
> iCardiac Technologies, which has advanced new technology to assess drug safety, has announced a second round of venture capital but is staying mum about just how much money it is getting.
> France's NicOx has posted positive data from a late-stage study of naproxcinod for osteoarthritis.
Sanofi-Aventis has launched a mid-stage study of a new seasonal flu vaccine that hopes to advance a completely new method to make vaccines. The vaccine is made from cell cultures as opposed to the
Dutch biotech Crucell has inked a joint venture deal with MedImmune to develop its bacterial antibodies to treat hospital-acquired infections. MedImmune has agreed to provide upfront, annual and
> Crucell says you shouldn't blame its technology for the failure of Merck's
Press Release: Crucell N.V. Announces STAR(TM) Research License Agreement With Novo Nordisk